BioSpace News Archive

Osmotica Pharmaceuticals plc announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Cantor Virtual Global Healthcare Conference 2021 as follows: Date: Monday, September 27, 2021 Time: 10:00 a.m. Eastern Time

Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders announced today that a peer-reviewed paper showed significantly lower seizure risk with NeuroStar® Advanced Therapy for Mental Health than with TMS treatments that claim deeper stimulation with H-Coil technology.

Masimo announced that Founder, Chairman, and CEO Joe Kiani has been appointed by President Joe Biden to the President’s Council of Advisors on Science and Technology.

Amplitude Healthcare Acquisition Corporation announced that its stockholders voted to approve the previously announced business combination with Jasper Therapeutics, Inc., a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell, and all other proposals presented at AMHC’’s special shareholder’s meeting held on September 22, 2021.

Synlogic a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced the pricing of its underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $3.00 per share.

Axonics, Inc. announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office has issued final written decisions on three additional Medtronic patents that Axonics is contesting.

Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine

Ascentage Pharma (6855.HK), today announced that its novel MDM2-p53 inhibitor alrizomadlin (APG-115) has been granted a Fast Track Designation (FTD) by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma, relapsed/refractory to prior immuno-oncologic agent (IO) treatments.

SomaLogic, Inc., a leader in AI-data driven proteomics technology, today is announcing upcoming conference participation in addition to its analyst meeting.

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), today announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for Sintilimab in combination with chemotherapy (cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil) for the first-line treatment of esophageal squamous cell carcinoma (ESCC).